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Abstract
The use of patent citations as a measure of patent "quality" increased dramatically in
recent years. I estimate the hazard of patent citation, and find evidence of unobserved
heterogeneity. Hazard estimation provides a means to separate patent quality from
citation "inflation."
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1 Introduction
In recent years the use of patent citations has proliferated in the economic literature. Ap-
plications abound in estimations of patent value, firm value, innovative performance, and
strategic behavior. This is due, in part, to the recent availability of NBER patent citation
data (Hall, Jaffe and Trajtenberg 2001). That project was undertaken because of a recogni-
tion that simple patent counts are noisy measures of innovative output (Trajtenberg 1990).
A patent citation is very similar to a bibliographic citation: an innovation may be partly
based on an earlier patented innovation. The inventor is required to disclose all “prior art”
related to the patented invention. Particularly novel patented innovations will be the subject
of greater citation. For this reason, the number of citations received by a patent (forward
citations) has been used in the literature as a measure of the innovative output embodied
in the technology.
Three applications of patent citations dominate the innovation literature in economics:
measuring patent “quality” (Trajtenberg 1990, Hagedoorn and Cloodt 2003); measuring
knowledge flows and spillovers (Jaffe, Trajtenberg and Henderson 1993, Moretti 2004); and
investigating strategic behavior by firms (Podolny, Stuart and Hannan 1996, Lanjouw and
Schankerman 2001, Marco 2005). These applications impute some real economic value to
patent citations: they signal either patent quality (value), or some transfer of knowledge
from one party to another.
This note investigates patent citations using parametric and non-parametric hazard
estimation. Hazard estimation is valuable in this context because the distribution of patent
citations is truncated due to unobserved future citation behavior. Estimates show that
there is unobserved heterogeneity in citation rates among patents. The results highlight
the need for researchers to understand the consequences of dynamics in relying on citation
measures, especially in cross-sectional estimation.
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2 Data
Data for the empirical analysis come from the NBER Patent Citation Datafile, described in
great detail by Hall et al. (2001). I use a random sample of 20,000 patents issued between
1975 and 1995, including information on backward citations and forward citations.
Backward citations are citations made by a patent to previously issued patents. Forward
citations are citations received by a patent from subsequently issued patents. In contrast
to backward citations, the number of forward citations changes over time, even beyond
the patent expiration. I normalize the number of forward citations at a given date by the
patent’s age to separate the effects of age and prior citations on the citation hazard rate
(citation rate). The heterogeneity results below are robust to different measures of forward
citations.
Forward citation counts present a problem in cross-sectional research. Younger patents
are bound to have fewer citations than otherwise identical older patents; that is, the distri-
bution of forward citations is truncated as described by Hall et al. (2001). The truncated
distribution must be accounted for in some way. Additionally, there is evidence of citation
inflation: the propensity to cite may be increasing for reasons unrelated to patent qual-
ity. The inflation may lead to time-inconsistency in equating citations to patent quality
(Hall et al. 2001). This note investigates the distribution of forward citation using a haz-
ard model, which corrects for truncation. Additionally, I make recommendations for using
hazard estimation to account for citation inflation.
Control variables include the number of patent claims (explained below), age, the year of
patent grant, and indicator variables for technology and type of patent assignee. I include
two time dummies to account for changes in the patent system in 1982-1984. Only the
forward citation count and age vary over time. Because I use time varying covariates, each
patent has multiple observations: one at birth and one for each forward citation. In total,
there are over 105,000 citations to the 20,000 patents.
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3 Analysis
In discrete terms, the hazard function, h(t), is the probability that a patent will receive
a citation given that it has survived for t years since its last citation. It is defined as
h (t) = f(t)1−F (t) , where f(t) and F (t) are the probability density and cumulative probability
functions for the random variable τ , the time until failure (citation).
I estimate the hazard function using a Weibull distribution because of the flexibility of
the functional form:1
h(t,X) = λρ(λt)ρ−1 (1)
where the parameter λ is defined as
λ = eXβ+ε. (2)
The parameters ρ and β are estimated using dataX. In the Weibull specification, ρ indicates
duration dependence. If ρ = 1, the Weibull reduces to an exponential distribution in which
the hazard is constant over time. Positive duration dependence occurs when ρ > 1 and
indicates that the citation hazard rate increases as the patent ages. ρ < 1 indicates negative
duration dependence.
I test for unobserved heterogeneity by estimating a frailty model. The hazard function
for observation j for patent n is specified as
h(tnj |Xnj , αn) = αnh(tnj |Xnj), (3)
where αn (the “frailty”) follows a gamma distribution with mean one and variance θ (the
degree of heterogeneity). θ = 0 implies no unobserved heterogeneity–the standard Weibull
hazard model. The null hypothesis of θ = 0 can be tested using a Likelihood Ratio test.
The frailty model is essentially a random effects model for hazard estimation. If there
exists unobserved heterogeneity among patents–making some more prone to citation than
others based on unobservable characteristics–then an interesting result can occur. One
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can observe a decreasing duration dependence in the population, even when individual-level
duration dependence is increasing.2
Estimation of Equation 3 proceeds via maximum likelihood, with censored observations
incorporated much like the Tobit model (Greene 1993). The log-likelihood function is
lnL =
!
uncensored
h (t|β, ρ, θ) +
!
all
ln (1− F (t|β, ρ, θ)) . (4)
The first column of Table 1 reports the standard hazard estimation using a Weibull
distribution; the second column estimates a frailty model. Coefficients are expressed as
hazard ratios, where a value above one indicates a positive impact on the hazard rate.
The current number of forward citations (normalized by age) tends to increase the
hazard rate of receiving a forward citation. This potentially accounts for some heterogeneity
because forward citations may beget forward citations. The number of claims and the
number of backward citations also increase the hazard rate. Backward citations account
for patenting areas where the propensity to cite is higher, and more claims may represent
patents with broader scope (Lanjouw and Schankerman 2001). As expected, patent age has
a negative impact on the citation rate and citation rates differ significantly across technology
classes.
Three results merit emphasis. First, the significance of θ indicates the presence of un-
observed heterogeneity: there is positive duration dependence for individual patents while
the population rate exhibits negative duration dependence (Figure 1). That is, individual
patents have increasing hazard rates, but the frailty effect generates a lognormal-like distri-
bution for the population. That there exists unobserved heterogeneity should not come as
a surprise to scholars who use patent citations as a measure for patent quality. If quality is
otherwise unobservable, then one should expect θ to be significant if quality and citations
are correlated.3
Second, even though age has a negative impact on the hazard rate, individual hazard
rates are hump-shaped in age (Figure 2). Importantly, the citation frequency in the pop-
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ulation falls after three years whereas the estimated citation hazard rate increases for the
first seven years.4 Again, this is a consequence of the frailty effect.
Lastly, the parameter coefficients on the technology dummies in Table 1 suggest that
there are differences in the hazard rate across technologies; non-parametric estimates con-
firm this. Figure 3 shows the Kaplan-Meier estimated hazard rates for different technology
groups. While the overall shape of the hazards is similar, the first panel shows that citation
rates for Medical patents and Computer and Communication patents differ from those for
other technology classes. Even within classes, there are differences among subclasses (e.g.,
Medical patents in panel two).
4 Conclusion
This note shows that there is unobserved heterogeneity in the rate of patent citation, and
that individual hazards exhibit positive duration dependence despite the average hump-
shaped hazard rate over the age of the patent. The results highlight the need for care in
interpreting the marginal effects of forward citations on other variables of interest, such as
firm value. At the least they must be interpreted in light of the fact that the citation rate
changes over the life of a patent; at best, one would want to model citation dynamics. An
alternative would be to include as regressors those factors that influence the rate of forward
citations, e.g., the industry or technology group, the year of patent grant, or the observed
life of the patent. That approach has two limitations. First, it does not account for the
clear non-linearity in citation rates. Second, it does not allow the researcher to separately
identify direct effects of patent citations from the independent effects of other regressors,
such as industry or technology.
Researchers have expressed concern that citation inflation may bias the estimated effect
of citations on other variables of interest. Indeed, it is difficult to separate the effects of
inflation from those of patent quality. If researchers are able to ascertain those factors that
are correlated to citation inflation rather than quality, then hazard estimation suggests the
rendering of new metrics for patent quality.
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By estimating a hazard rate based only on inflationary factors, residuals can be used
to measure latent patent quality. For example, the difference between actual citation lags
and predicted citation lags may be a better measure of patent quality than simple citation
counts. Alternatively, the ratio of observed citations to predicted citations may represent a
proxy of patent quality. The advantage of such constructs is that they can be calculated as
time-invariant values that are not subject to censoring.
Of course, the proposed methods for measuring patent quality are predicated upon a
correlation between unobserved heterogeneity in patent citation and patent quality. This is
an area left for future research.
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Notes
1I tested the Weibull distribution against exponential and lognormal distributions. The
Weibull performed better on a range of criteria including the Akaike Infomation Criterion
(AIC).
2In mortality studies, some subjects may be more “frail” than others. Frail patients die
early, leaving a more robust population alive. If the frailty is unobservable ex ante, then
there will be an apparent decrease in mortality over analysis time. It is a type of fallacy of
composition. In the patent context, highly cited patents drop out early and the clock on
analysis time (duration) is reset. As the duration of a spell increases, weakly cited patents
remain, leading to an apparently lower citation rate.
3This should not be taken to mean that evidence of unobserved heterogeneity implies
that patents do–in fact–measure quality; only that the two are consistent.
4Adding age2 does not impact this result.
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Table 1: Forward Citation Rate: Hazard Estimation
Variable
Claims 1.004 (0.000) * 1.002 (0.000) *
Forward/Age 1.290 (0.002) * 1.546 (0.006) *
Age 0.659 (0.001) * 0.670 (0.001) *
Citations made 1.004 (0.000) * 1.004 (0.001) *
Foreign 0.956 (0.007) * 0.970 (0.008) *
Individual 1.014 (0.030) 1.013 (0.038)
Grant year 1.062 (0.001) * 1.073 (0.002) *
Pre-1982 grant 1.510 (0.019) * 1.663 (0.026) *
Post-1984 grant 0.793 (0.010) * 0.730 (0.012) *
Chemicals 1.079 (0.011) * 1.043 (0.013) *
Comp./Comm. 1.267 (0.014) * 1.154 (0.017) *
Medical 1.232 (0.015) * 1.155 (0.019) *
Electronics 1.049 (0.011) * 1.039 (0.014) *
Mechanical 0.994 (0.010) 0.984 (0.012)
p,  Weibull parameter 3.606 (0.013) * 3.492 (0.008) *
θ, heterogeneity parameter -- 0.063 (0.002) *
Log-likelihood 106,305 109,549
LR test χ2(14) 128,660 76,240
Notes:
105,327 citations for 20,000 patents.
Dependent variable is duration until failure. All specifications assume the Weibull distribution.
Coefficients expressed as hazard ratios. Standard errors in parentheses. * significant at 1%.
Likelihood-ratio test of θ = 0: χ2(1) = 6487.
Weibull Frailty
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Figure 1: Estimated Forward Citation Hazard Rate
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Figure 2: Forward Citations by Age of Patent
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Figure 3: Non-parametric Hazard Estimates
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